
Invivyd Inc (IVVD) Stock Forecast & Price Target
Invivyd Inc (IVVD) Analyst Ratings
Bulls say
Invivyd Inc is positioned favorably in the expanding market for pandemic-related antibody treatments, projected to reach $3-4 billion globally by 2030, with its innovative products incorporating advanced half-life extension technology and biophysical characteristics suggesting best-in-class potential. The company’s VBY329 candidate showcases impressive antiviral potency and superior neutralization capabilities against resistant variants, indicating a strong competitive edge in addressing evolving viral threats. Encouraging Phase 1/2 safety data contributes to high confidence in the long-term utility of these therapies, reinforcing the company’s prospects for future regulatory and commercial success.
Bears say
Invivyd Inc. is centered on developing antibody-based therapies aimed at enhancing protection against infectious diseases like COVID-19; however, the company grapples with challenges regarding the broader acceptance and utility of its products within a competitive market. Emphasis on the limitations of existing vaccines, including concerns over waning efficacy and public hesitancy, further compounds the difficulty in securing a favorable position in the evolving landscape of viral interventions. Additionally, while the projected 2024 COVID vaccine revenue of approximately $4 billion highlights a significant total addressable market, it underscores the intense competition and the potential risk associated with reliance on an environment characterized by diminishing vaccine effectiveness.
This aggregate rating is based on analysts' research of Invivyd Inc and is not a guaranteed prediction by Public.com or investment advice.
Invivyd Inc (IVVD) Analyst Forecast & Price Prediction
Start investing in Invivyd Inc (IVVD)
Order type
Buy in
Order amount
Est. shares
0 shares